Real-world outcomes of patients treated with ≥17 cycles of pembrolizumab monotherapy as first-line therapy and for previously treated advanced NSCLC: multicenter observational study in France.
Saved in:
| Title: | Real-world outcomes of patients treated with ≥17 cycles of pembrolizumab monotherapy as first-line therapy and for previously treated advanced NSCLC: multicenter observational study in France. |
|---|---|
| Authors: | Pérol M; Department of Medical Oncology, Centre Léon Bérard, Lyon, France. Electronic address: maurice.perol@lyon.unicancer.fr., Audigier-Valette C; Department of Thoracic Oncology, Hôpital Sainte Musse, Toulon, France., Léna H; Centre hospitalier universitaire Pontchaillou, Rennes, France., Massiani MA; Department of Medical Oncology, Institut Curie, Saint-Cloud, France., Quantin X; Institut du Cancer de Montpellier, Montpellier, France., Santorelli M; Value & Implementation Outcomes Research, Oncology, Merck & Co., Inc., Rahway, NJ, USA., Apert M; Outcomes Research, MSD France, Puteaux, France., Spampinato A; Medical Affairs, MSD France, Puteaux, France., Burke T; Outcomes Research, MRL, Merck & Co. Inc., Rahway, NJ, USA., Chouaid C; Pneumonology Unit, Centre Hospitalier Intercommunal, Créteil, France. |
| Source: | Respiratory medicine and research [Respir Med Res] 2026 May; Vol. 89, pp. 101238. Date of Electronic Publication: 2025 Dec 10. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Masson SAS Country of Publication: France NLM ID: 101746324 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2590-0412 (Electronic) Linking ISSN: 25900412 NLM ISO Abbreviation: Respir Med Res Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41468718 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Real-world outcomes of patients treated with ≥17 cycles of pembrolizumab monotherapy as first-line therapy and for previously treated advanced NSCLC: multicenter observational study in France. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Pérol+M%22">Pérol M</searchLink>; Department of Medical Oncology, Centre Léon Bérard, Lyon, France. Electronic address: maurice.perol@lyon.unicancer.fr.<br /><searchLink fieldCode="AU" term="%22Audigier-Valette+C%22">Audigier-Valette C</searchLink>; Department of Thoracic Oncology, Hôpital Sainte Musse, Toulon, France.<br /><searchLink fieldCode="AU" term="%22Léna+H%22">Léna H</searchLink>; Centre hospitalier universitaire Pontchaillou, Rennes, France.<br /><searchLink fieldCode="AU" term="%22Massiani+MA%22">Massiani MA</searchLink>; Department of Medical Oncology, Institut Curie, Saint-Cloud, France.<br /><searchLink fieldCode="AU" term="%22Quantin+X%22">Quantin X</searchLink>; Institut du Cancer de Montpellier, Montpellier, France.<br /><searchLink fieldCode="AU" term="%22Santorelli+M%22">Santorelli M</searchLink>; Value & Implementation Outcomes Research, Oncology, Merck & Co., Inc., Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Apert+M%22">Apert M</searchLink>; Outcomes Research, MSD France, Puteaux, France.<br /><searchLink fieldCode="AU" term="%22Spampinato+A%22">Spampinato A</searchLink>; Medical Affairs, MSD France, Puteaux, France.<br /><searchLink fieldCode="AU" term="%22Burke+T%22">Burke T</searchLink>; Outcomes Research, MRL, Merck & Co. Inc., Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Chouaid+C%22">Chouaid C</searchLink>; Pneumonology Unit, Centre Hospitalier Intercommunal, Créteil, France. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101746324%22">Respiratory medicine and research</searchLink> [Respir Med Res] 2026 May; Vol. 89, pp. 101238. <i>Date of Electronic Publication: </i>2025 Dec 10. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Masson+SAS%22">Elsevier Masson SAS </searchLink><i>Country of Publication: </i>France <i>NLM ID: </i>101746324 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2590-0412 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2225900412%22">25900412 </searchLink><i>NLM ISO Abbreviation: </i>Respir Med Res <i>Subsets: </i>MEDLINE; In Process |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41468718 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.resmer.2025.101238 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 101238 Titles: – TitleFull: Real-world outcomes of patients treated with ≥17 cycles of pembrolizumab monotherapy as first-line therapy and for previously treated advanced NSCLC: multicenter observational study in France. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Pérol M – PersonEntity: Name: NameFull: Audigier-Valette C – PersonEntity: Name: NameFull: Léna H – PersonEntity: Name: NameFull: Massiani MA – PersonEntity: Name: NameFull: Quantin X – PersonEntity: Name: NameFull: Santorelli M – PersonEntity: Name: NameFull: Apert M – PersonEntity: Name: NameFull: Spampinato A – PersonEntity: Name: NameFull: Burke T – PersonEntity: Name: NameFull: Chouaid C IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 05 Text: 2026 May Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 2590-0412 Numbering: – Type: volume Value: 89 Titles: – TitleFull: Respiratory medicine and research Type: main |
| ResultId | 1 |
